The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | The role of APOBECs in myeloma & incorporating APOBECs in current risk stratification models
Florian Kuchenbauer, MD, PhD, BC Cancer, Vancouver, Canada, comments on the role of APOBECs in multiple myeloma, highlighting how the inclusion of APOBECs into current risk stratification models can help better stratify patients with multiple myeloma, and discussing the impact of APOBECs in inflammation. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
